| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension | 7 | 2019 | 748 | 1.210 |
Why?
|
| Pharmacogenetics | 7 | 2019 | 456 | 0.910 |
Why?
|
| Antihypertensive Agents | 4 | 2018 | 256 | 0.820 |
Why?
|
| Cardiovascular Agents | 4 | 2015 | 57 | 0.790 |
Why?
|
| Dyslipidemias | 3 | 2018 | 107 | 0.740 |
Why?
|
| Atrial Fibrillation | 4 | 2014 | 415 | 0.630 |
Why?
|
| Cardiovascular Diseases | 7 | 2015 | 752 | 0.610 |
Why?
|
| Heart Failure | 6 | 2019 | 1376 | 0.610 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2019 | 60 | 0.590 |
Why?
|
| Risk Reduction Behavior | 1 | 2019 | 100 | 0.580 |
Why?
|
| Cardiology | 3 | 2015 | 120 | 0.560 |
Why?
|
| Students, Medical | 1 | 2023 | 433 | 0.540 |
Why?
|
| Coronary Disease | 5 | 2000 | 221 | 0.480 |
Why?
|
| Physicians | 1 | 2023 | 668 | 0.470 |
Why?
|
| Adrenergic beta-Antagonists | 4 | 2005 | 108 | 0.390 |
Why?
|
| Practice Guidelines as Topic | 3 | 2018 | 1054 | 0.370 |
Why?
|
| Hemorrhage | 1 | 2014 | 289 | 0.350 |
Why?
|
| Anticoagulants | 1 | 2014 | 455 | 0.320 |
Why?
|
| Lipids | 1 | 2012 | 277 | 0.320 |
Why?
|
| Proteinuria | 1 | 2010 | 69 | 0.310 |
Why?
|
| Myocardial Ischemia | 3 | 2005 | 140 | 0.300 |
Why?
|
| Hemangioma, Cavernous, Central Nervous System | 2 | 2025 | 257 | 0.300 |
Why?
|
| Cerebral Hemorrhage | 2 | 2025 | 362 | 0.300 |
Why?
|
| Humans | 44 | 2025 | 93132 | 0.260 |
Why?
|
| Physician-Patient Relations | 3 | 2023 | 561 | 0.260 |
Why?
|
| Drug Prescriptions | 2 | 2019 | 150 | 0.250 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2010 | 256 | 0.240 |
Why?
|
| Clinical Decision-Making | 2 | 2019 | 290 | 0.230 |
Why?
|
| Disease Outbreaks | 1 | 2005 | 147 | 0.220 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2025 | 393 | 0.210 |
Why?
|
| Metabolic Syndrome | 1 | 2005 | 122 | 0.210 |
Why?
|
| Primary Prevention | 2 | 2000 | 87 | 0.200 |
Why?
|
| Faculty | 1 | 2023 | 35 | 0.190 |
Why?
|
| Point-of-Care Systems | 3 | 2019 | 150 | 0.190 |
Why?
|
| Electric Countershock | 1 | 2003 | 74 | 0.190 |
Why?
|
| Pharmacogenomic Testing | 3 | 2019 | 107 | 0.190 |
Why?
|
| Cardiac Imaging Techniques | 2 | 2012 | 22 | 0.180 |
Why?
|
| Communication | 2 | 2023 | 433 | 0.180 |
Why?
|
| Cardiac Catheterization | 3 | 2012 | 295 | 0.180 |
Why?
|
| Heart Septal Defects, Atrial | 2 | 1993 | 61 | 0.180 |
Why?
|
| Societies, Medical | 2 | 2018 | 618 | 0.170 |
Why?
|
| Thoracic Surgery | 2 | 2012 | 62 | 0.170 |
Why?
|
| United States | 9 | 2018 | 7581 | 0.170 |
Why?
|
| Stroke Volume | 2 | 2019 | 434 | 0.160 |
Why?
|
| Hypertriglyceridemia | 1 | 2000 | 71 | 0.160 |
Why?
|
| Proof of Concept Study | 1 | 2019 | 56 | 0.150 |
Why?
|
| Hypercholesterolemia | 1 | 2000 | 160 | 0.150 |
Why?
|
| Physician's Role | 2 | 2017 | 175 | 0.150 |
Why?
|
| Risk Factors | 6 | 2012 | 5900 | 0.150 |
Why?
|
| Hemangioma, Cavernous | 1 | 2019 | 66 | 0.150 |
Why?
|
| Decision Support Systems, Clinical | 2 | 2017 | 122 | 0.150 |
Why?
|
| Precision Medicine | 3 | 2019 | 457 | 0.150 |
Why?
|
| Diltiazem | 1 | 1998 | 6 | 0.140 |
Why?
|
| Drug Labeling | 2 | 2017 | 41 | 0.140 |
Why?
|
| Risk | 2 | 2018 | 651 | 0.140 |
Why?
|
| Prescription Drugs | 1 | 2019 | 38 | 0.140 |
Why?
|
| Serine Proteinase Inhibitors | 1 | 2018 | 25 | 0.140 |
Why?
|
| Sterols | 1 | 2018 | 19 | 0.140 |
Why?
|
| Aged | 14 | 2025 | 20395 | 0.140 |
Why?
|
| Intestinal Absorption | 1 | 2018 | 125 | 0.130 |
Why?
|
| Dyspnea | 3 | 1996 | 86 | 0.130 |
Why?
|
| Echocardiography | 5 | 2012 | 748 | 0.130 |
Why?
|
| Blood Pressure Determination | 1 | 2018 | 69 | 0.130 |
Why?
|
| Medical Order Entry Systems | 1 | 2017 | 27 | 0.130 |
Why?
|
| Primary Health Care | 1 | 2000 | 369 | 0.130 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2005 | 1229 | 0.130 |
Why?
|
| Treatment Outcome | 7 | 2025 | 9070 | 0.120 |
Why?
|
| Female | 19 | 2025 | 48542 | 0.120 |
Why?
|
| Anticholesteremic Agents | 1 | 2018 | 154 | 0.120 |
Why?
|
| Tachycardia, Ventricular | 1 | 1998 | 175 | 0.120 |
Why?
|
| Male | 17 | 2025 | 44355 | 0.120 |
Why?
|
| Dobutamine | 1 | 1996 | 38 | 0.120 |
Why?
|
| Ventricular Outflow Obstruction | 1 | 1996 | 21 | 0.120 |
Why?
|
| Adrenergic beta-Agonists | 1 | 1996 | 69 | 0.120 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2019 | 603 | 0.110 |
Why?
|
| Hypotension | 1 | 1996 | 71 | 0.110 |
Why?
|
| Evidence-Based Medicine | 4 | 2005 | 451 | 0.110 |
Why?
|
| Echocardiography, Doppler | 1 | 1996 | 134 | 0.110 |
Why?
|
| Clinical Medicine | 1 | 2015 | 26 | 0.110 |
Why?
|
| Exercise Test | 1 | 1996 | 151 | 0.110 |
Why?
|
| Intestines | 1 | 2018 | 433 | 0.110 |
Why?
|
| Life Style | 3 | 2000 | 183 | 0.110 |
Why?
|
| Disease Progression | 1 | 2019 | 1529 | 0.110 |
Why?
|
| Posture | 2 | 1993 | 121 | 0.110 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2017 | 618 | 0.110 |
Why?
|
| Genome, Human | 1 | 2019 | 823 | 0.100 |
Why?
|
| Mitral Valve Prolapse | 1 | 1993 | 18 | 0.100 |
Why?
|
| Program Development | 1 | 2014 | 129 | 0.100 |
Why?
|
| Middle Aged | 14 | 2025 | 27535 | 0.100 |
Why?
|
| Severity of Illness Index | 4 | 2001 | 1910 | 0.100 |
Why?
|
| Ambulatory Care | 1 | 2014 | 195 | 0.090 |
Why?
|
| Ventricular Function, Left | 1 | 1996 | 517 | 0.090 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2018 | 1000 | 0.090 |
Why?
|
| Blood Proteins | 1 | 1992 | 144 | 0.090 |
Why?
|
| Lipoproteins | 1 | 1992 | 136 | 0.090 |
Why?
|
| Counterpulsation | 1 | 1992 | 21 | 0.090 |
Why?
|
| Patient Selection | 3 | 2015 | 688 | 0.090 |
Why?
|
| Antiphospholipid Syndrome | 1 | 1992 | 17 | 0.090 |
Why?
|
| Academic Medical Centers | 1 | 2014 | 396 | 0.080 |
Why?
|
| Risk Assessment | 2 | 2014 | 2434 | 0.080 |
Why?
|
| Blood Pressure | 2 | 2010 | 887 | 0.080 |
Why?
|
| Insulin Resistance | 2 | 2005 | 379 | 0.080 |
Why?
|
| General Practitioners | 1 | 2010 | 10 | 0.080 |
Why?
|
| Double-Blind Method | 4 | 2025 | 1727 | 0.080 |
Why?
|
| Adult | 8 | 2025 | 27849 | 0.080 |
Why?
|
| Biomarkers | 2 | 2018 | 1905 | 0.080 |
Why?
|
| Diabetes Complications | 2 | 2000 | 167 | 0.080 |
Why?
|
| Thrombosis | 1 | 1992 | 308 | 0.070 |
Why?
|
| Diuretics | 2 | 1999 | 75 | 0.070 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 2 | 1999 | 96 | 0.070 |
Why?
|
| Coronary Artery Disease | 1 | 2012 | 371 | 0.070 |
Why?
|
| Cardiomegaly | 1 | 1988 | 111 | 0.060 |
Why?
|
| Aged, 80 and over | 5 | 2025 | 7039 | 0.060 |
Why?
|
| Models, Biological | 1 | 2014 | 1768 | 0.060 |
Why?
|
| Oxygen | 1 | 1991 | 749 | 0.060 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2010 | 557 | 0.060 |
Why?
|
| Algorithms | 1 | 2014 | 1948 | 0.060 |
Why?
|
| Cerebrovascular Disorders | 2 | 1999 | 138 | 0.060 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2005 | 56 | 0.060 |
Why?
|
| Hyperlipidemias | 1 | 2005 | 90 | 0.060 |
Why?
|
| Prospective Studies | 3 | 2019 | 4546 | 0.050 |
Why?
|
| Stroke | 1 | 2014 | 1073 | 0.050 |
Why?
|
| Vascular Surgical Procedures | 1 | 2005 | 150 | 0.050 |
Why?
|
| Heart-Assist Devices | 1 | 1992 | 883 | 0.050 |
Why?
|
| Obesity | 2 | 2000 | 1014 | 0.050 |
Why?
|
| Preoperative Care | 1 | 2005 | 404 | 0.050 |
Why?
|
| Myocardial Infarction | 2 | 1999 | 375 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 3814 | 0.050 |
Why?
|
| Diet | 1 | 2005 | 461 | 0.040 |
Why?
|
| Survival Analysis | 2 | 2005 | 1518 | 0.040 |
Why?
|
| Coronary Circulation | 2 | 1992 | 95 | 0.040 |
Why?
|
| Magnetic Resonance Imaging, Cine | 2 | 2012 | 145 | 0.040 |
Why?
|
| Coronary Angiography | 2 | 2012 | 232 | 0.040 |
Why?
|
| Prognosis | 2 | 2001 | 3890 | 0.040 |
Why?
|
| Contraindications | 1 | 2001 | 65 | 0.040 |
Why?
|
| Microvascular Angina | 1 | 2000 | 1 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2025 | 3450 | 0.040 |
Why?
|
| Niacin | 1 | 2000 | 37 | 0.040 |
Why?
|
| Morbidity | 1 | 2001 | 162 | 0.040 |
Why?
|
| Guideline Adherence | 2 | 2012 | 237 | 0.040 |
Why?
|
| Physical Examination | 1 | 2001 | 143 | 0.040 |
Why?
|
| Family Practice | 1 | 2000 | 71 | 0.040 |
Why?
|
| Triglycerides | 1 | 2000 | 231 | 0.040 |
Why?
|
| Hypolipidemic Agents | 1 | 2000 | 96 | 0.040 |
Why?
|
| Genotype | 2 | 2015 | 1866 | 0.040 |
Why?
|
| Cause of Death | 1 | 2000 | 271 | 0.040 |
Why?
|
| Administration, Oral | 2 | 1998 | 655 | 0.040 |
Why?
|
| Young Adult | 2 | 2025 | 6922 | 0.040 |
Why?
|
| rhoA GTP-Binding Protein | 1 | 2019 | 87 | 0.040 |
Why?
|
| Drug Recalls | 1 | 2019 | 12 | 0.040 |
Why?
|
| Heart Diseases | 1 | 2001 | 258 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2001 | 753 | 0.040 |
Why?
|
| Calcium Channel Blockers | 1 | 1999 | 118 | 0.040 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2001 | 258 | 0.040 |
Why?
|
| Chicago | 2 | 2014 | 1452 | 0.040 |
Why?
|
| Cholesterol | 1 | 2000 | 364 | 0.040 |
Why?
|
| Renal Insufficiency | 1 | 1999 | 97 | 0.040 |
Why?
|
| Proprotein Convertase 9 | 1 | 2018 | 28 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 1998 | 400 | 0.030 |
Why?
|
| Guidelines as Topic | 1 | 2019 | 163 | 0.030 |
Why?
|
| Research | 1 | 2019 | 250 | 0.030 |
Why?
|
| Exercise | 1 | 2000 | 353 | 0.030 |
Why?
|
| Digoxin | 1 | 1997 | 21 | 0.030 |
Why?
|
| Predictive Value of Tests | 2 | 2010 | 1703 | 0.030 |
Why?
|
| Health Personnel | 1 | 2019 | 234 | 0.030 |
Why?
|
| Smoking | 1 | 2000 | 647 | 0.030 |
Why?
|
| Disease Management | 1 | 2019 | 357 | 0.030 |
Why?
|
| Time Factors | 2 | 2005 | 5380 | 0.030 |
Why?
|
| Social Perception | 1 | 2017 | 92 | 0.030 |
Why?
|
| Recurrence | 1 | 1999 | 1188 | 0.030 |
Why?
|
| Cardiotonic Agents | 1 | 1997 | 87 | 0.030 |
Why?
|
| Drug Resistance | 1 | 1997 | 231 | 0.030 |
Why?
|
| Angina Pectoris | 1 | 1996 | 18 | 0.030 |
Why?
|
| Cardiac Output | 1 | 1996 | 141 | 0.030 |
Why?
|
| Attitude to Health | 1 | 2017 | 214 | 0.030 |
Why?
|
| Blood Flow Velocity | 1 | 1996 | 177 | 0.030 |
Why?
|
| Hospitalization | 1 | 2001 | 924 | 0.030 |
Why?
|
| Sympatholytics | 1 | 1994 | 5 | 0.030 |
Why?
|
| Clonidine | 1 | 1994 | 33 | 0.030 |
Why?
|
| Anesthesia, Local | 1 | 1994 | 29 | 0.030 |
Why?
|
| Incidence | 1 | 1999 | 1697 | 0.030 |
Why?
|
| Bupivacaine | 1 | 1994 | 48 | 0.030 |
Why?
|
| Cholecystectomy, Laparoscopic | 1 | 1994 | 52 | 0.030 |
Why?
|
| Analgesia | 1 | 1994 | 64 | 0.030 |
Why?
|
| Retrospective Studies | 3 | 2018 | 10128 | 0.030 |
Why?
|
| Heart Auscultation | 1 | 1993 | 3 | 0.020 |
Why?
|
| Endocarditis, Bacterial | 1 | 1993 | 37 | 0.020 |
Why?
|
| Anesthesia | 1 | 1994 | 173 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2012 | 2562 | 0.020 |
Why?
|
| Adolescent | 1 | 2025 | 9550 | 0.020 |
Why?
|
| Hospitals, University | 1 | 1992 | 188 | 0.020 |
Why?
|
| Pain, Postoperative | 1 | 1994 | 274 | 0.020 |
Why?
|
| Advisory Committees | 1 | 2012 | 90 | 0.020 |
Why?
|
| American Heart Association | 1 | 2012 | 106 | 0.020 |
Why?
|
| Angiography | 1 | 2012 | 192 | 0.020 |
Why?
|
| Equipment Failure | 1 | 1992 | 119 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2015 | 826 | 0.020 |
Why?
|
| Heart Ventricles | 1 | 1996 | 649 | 0.020 |
Why?
|
| Arrhythmias, Cardiac | 1 | 1993 | 222 | 0.020 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 1991 | 117 | 0.020 |
Why?
|
| Mitral Valve Insufficiency | 1 | 1993 | 175 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2019 | 2787 | 0.020 |
Why?
|
| Ventricular Function, Right | 1 | 1991 | 138 | 0.020 |
Why?
|
| Systole | 1 | 2010 | 81 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2017 | 3044 | 0.020 |
Why?
|
| Periodicals as Topic | 1 | 2012 | 166 | 0.020 |
Why?
|
| Awareness | 1 | 2010 | 89 | 0.020 |
Why?
|
| Prevalence | 1 | 1993 | 1318 | 0.020 |
Why?
|
| Comorbidity | 1 | 1992 | 1003 | 0.020 |
Why?
|
| Hemodynamics | 1 | 1992 | 712 | 0.020 |
Why?
|
| Age Factors | 1 | 1992 | 1898 | 0.020 |
Why?
|
| Hypoxia | 1 | 1993 | 672 | 0.020 |
Why?
|
| Patient Education as Topic | 1 | 2010 | 381 | 0.020 |
Why?
|
| Intermittent Claudication | 1 | 2005 | 19 | 0.010 |
Why?
|
| Nutrition Policy | 1 | 2005 | 12 | 0.010 |
Why?
|
| Aneurysm | 1 | 2005 | 57 | 0.010 |
Why?
|
| Premedication | 2 | 1994 | 57 | 0.010 |
Why?
|
| Extremities | 1 | 2005 | 170 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2005 | 984 | 0.010 |
Why?
|
| Logistic Models | 1 | 2005 | 1240 | 0.010 |
Why?
|
| Length of Stay | 1 | 2005 | 820 | 0.010 |
Why?
|
| Survival Rate | 1 | 2005 | 1945 | 0.010 |
Why?
|
| Ultrasonography, Doppler, Color | 1 | 2001 | 36 | 0.010 |
Why?
|
| Ventricular Dysfunction | 1 | 2001 | 24 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2005 | 916 | 0.010 |
Why?
|
| Heart Valve Diseases | 1 | 2001 | 100 | 0.010 |
Why?
|
| Enflurane | 1 | 1994 | 2 | 0.010 |
Why?
|
| Sufentanil | 1 | 1994 | 3 | 0.010 |
Why?
|
| Receptors, Adrenergic | 1 | 1994 | 14 | 0.010 |
Why?
|
| Diazepam | 1 | 1994 | 26 | 0.010 |
Why?
|
| Administration, Cutaneous | 1 | 1994 | 61 | 0.010 |
Why?
|
| Epinephrine | 1 | 1994 | 92 | 0.010 |
Why?
|
| Placebos | 1 | 1994 | 205 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2005 | 2552 | 0.010 |
Why?
|
| Urodynamics | 1 | 1994 | 126 | 0.010 |
Why?
|
| Nitrous Oxide | 1 | 1994 | 107 | 0.010 |
Why?
|
| Postoperative Care | 1 | 1994 | 232 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 1994 | 827 | 0.010 |
Why?
|
| Hydrocortisone | 1 | 1994 | 294 | 0.010 |
Why?
|
| Respiration | 1 | 1994 | 268 | 0.010 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 1994 | 249 | 0.010 |
Why?
|
| Surgical Procedures, Operative | 1 | 1994 | 217 | 0.010 |
Why?
|
| Heart Rate | 1 | 1994 | 505 | 0.010 |
Why?
|
| Electrocardiography | 1 | 1994 | 496 | 0.010 |
Why?
|
| Blood Glucose | 1 | 1994 | 866 | 0.010 |
Why?
|